Bioresorbable Drug Eluting Stent Market
The market for Bioresorbable Drug Eluting Stent was estimated at $881 million in 2024; it is anticipated to increase to $1.33 billion by 2030, with projections indicating growth to around $1.87 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Bioresorbable Drug Eluting Stent Market Outlook
Revenue, 2024
$881M
Forecast, 2034
$1.75B
CAGR, 2025 - 2034
7.1%
The Bioresorbable Drug Eluting Stent industry revenue is expected to be around $943.3 million in 2025 and expected to showcase growth with 7.1% CAGR between 2025 and 2034. The significant expansion of the Bioresorbable Drug Eluting Stent market can be attributed to a range of impactful reasons The introduction of cutting edge technologies and advancements in the healthcare sector has solidified the importance of these stents in percutaneous coronary intervention processes The increasing occurrence of ailments. Particularly coronary artery disease and peripheral artery disease. Is contributing to the rising need, for this product Furthermore the ability of the stent to be bioresorbable has played a role in gaining approval. These devices have shown results over the long term and have reduced the risk of late thrombotic events while also offering the potential, for restoring artery function.
The Bioresorbable Drug Eluting Stent marks an era in coronary stenting as it mimics the performance of a metal stent before gradually dissolving within the body over time to promote enhanced vessel healing and restoration to its natural state. These innovative stents find utility in treating conditions like coronary heart disease and peripheral artery disease with recent market observations indicating heightened interest, in tailored medical approaches and material science innovations.
Market Key Insights
- The Bioresorbable Drug Eluting Stent market is projected to grow from $880.8 million in 2024 to $1.75 billion in 2034. This represents a CAGR of 7.1%, reflecting rising demand across Coronary Artery Disease Treatment, Off-label Uses and Peripheral Artery Disease Treatment.
- Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Bioresorbable Drug Eluting Stent market and are expected to observe the growth CAGR of 4.6% to 6.8% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.2% to 9.8%.
- Transition like Technological Advancements has greater influence in U.S. and Germany market's value chain; and is expected to add $44 million of additional value to Bioresorbable Drug Eluting Stent industry revenue by 2030.
- The Bioresorbable Drug Eluting Stent market is set to add $868 million between 2024 and 2034, with manufacturer targeting Myocardial Infarction & Multivessel Coronary Artery Disease Application projected to gain a larger market share.
- With Increased prevalence of cardiovascular diseases, and Technological advancements in stent design, Bioresorbable Drug Eluting Stent market to expand 99% between 2024 and 2034.
Opportunities in the Bioresorbable Drug Eluting Stent
The increasing popularity of invasive surgeries is also leading to a significant rise in the demand for the Bioresorbable Drug Eluting Stent, in the market.
Growth Opportunities in North America and Asia Pacific
North America leads the way in the Bioresorbable Drug Eluting Stents market due to advancements in technology and substantial healthcare investments. Medicare offers benefits for treating coronary artery disease with these stents which is driving up demand. The competition in the region is intense with major players, like Abbott Laboratories taking the lead. Factors contributing to growth include a number of patients needing stents and policymakers prioritizing efforts to reduce hospital readmissions related to angina or heart attacks. Research and development efforts, in the realm of scaffolds are driving advancements and growth in the market.
The Asia Pacific region shows promise as a growing market for Bioresorbable Drug Eluting Stents due to the increasing prevalence of diseases and improved healthcare infrastructure accessibility in the regions countries like China and India where manufacturers such, as Biotronik and Terumo Corporation are engaged in competitive activities. Moreover. The high occurrence of diabetes. A risk factor for atherosclerotic conditions and the main reason, for stent insertion. Is contributing to the markets growth.
Market Dynamics and Supply Chain
01
Driver: Increased Prevalence of Cardiovascular Diseases, and Favorable Reimbursement Policies
The increasing global occurrence of heart diseases presents an opportunity for Bioresorbable Drug Eluting Stents in the market sector. They are also widely utilized during angioplasty procedures for treating heart conditions which contributes to their growing popularity. Their special feature of being biodegradable and drug releasing enhances the effectiveness of interventions making them a preferred choice, among medical professionals. The establishment of favorable reimbursement policies worldwide for cardiac procedures employing Bioresorbable Drug Eluting Stents has also positively influenced their market growth. These policies aim to lower the financial burden on patients, encouraging an increased adoption of technologically advanced stents for optimal treatment results.
The progress in stent technology has also led to the rise of Drug Eluting Stents in the market due to advancements like using biodegradable materials and targeted drug delivery features that enhance their efficacy and minimize complications during surgeries, for various cardiac procedures.
02
Restraint: Regulatory Hurdles
The bioresorbable drug coated stent industry faces regulatory obstacles as these devices must pass strict evaluations and receive endorsements from institutions like the FDA and EMA in Europe. Due to the demanding trials mandated for safety and effectiveness by these regulatory bodies a number of stents in development might experience delays or barriers, to market entry. Such hurdles could lead to market expansion and limited patient availability of this cutting edge medical technology influencing market trends and consumer demand directly.
03
Opportunity: Technological Advancements in Stent Design and Adoption in Untapped Developing Markets
The Bioresorbable Drug Eluting Stent market presents promising growth prospects due to the growing emphasis placed upon advancements in the industry sector. Innovative bioresorbable technologies and developed design improvements are gaining recognition for their ability to alleviate the typical complications linked with permanent metallic stents. Their advantages in terms of minimizing the need, for surgeries and cutting down overall medical expenses are expected to propel market expansion forward.
The field of Drug Eluting Stents in developing countries still has room to grow significantly with South Asia and Sub Saharan Africa holding vast opportunities for expansion due to the rising cases of cardiovascular diseases in these regions. The increasing healthcare infrastructure and improving conditions are also driving the demand for advanced medical devices like Bioresorbable Drug Eluting Stents, in these areas.
04
Challenge: High Costs and Limitations in Insurance Coverage
The production, development, and supply of bioresorbable drug eluting stents require significant financial investment, making them a high-cost product. Furthermore, the lack of sufficient insurance coverage in many regions makes these stents unaffordable for numerous patients.
Supply Chain Landscape
1
Raw Material Procurement
DupontRoyal DSM
2
Stent Production & Drug Loading
Orbusneich MedicalBoston Scientific Corporation
3
Packaging & Sterilization
Johnson and JohnsonMedtronic PLC
4
Distribution & Marketing
Abbott LaboratoriesCardinal Health
1
Raw Material Procurement
DupontRoyal DSM
2
Stent Production & Drug Loading
Orbusneich MedicalBoston Scientific Corporation
3
Packaging & Sterilization
Johnson and JohnsonMedtronic PLC
4
Distribution & Marketing
Abbott LaboratoriesCardinal Health
Use Cases of Bioresorbable Drug Eluting Stent in Coronary Artery Disease Treatment & Off-label Uses
Coronary Artery Disease Treatment : The bioresorbable drug eluting stent is predominantly employed in the treatment of coronary artery disease. They are designed to keep the clogged arteries open and prevent heart attacks. These stents gradually vanish or resorb over time, decreasing the possibility of long-term complications and improving the patients quality of life. Major players such as Abbott Vascular and Boston Scientific have a strong market position, delivering high-quality stents that merge design innovations, drug delivery technology, and bioresorbable material science.
Peripheral Artery Disease Treatment : Bioresorbable drug eluting stents are extensively used for peripheral artery disease treatment as well. These stents act as minuscule scaffolds that prevent the artery from closing again after the angioplasty procedure. Companies like Medtronic and Cook Medical are known for forging ahead with advanced stents, leveraging superior alloy technology, and optimizing stent designs for enhanced flexibility and radial strength, thereby ensuring a strong market presence.
Off-label Uses : Beyond the core applications, bioresorbable drug eluting stents are being explored for their potential off-label uses. Owing to the stents bioresorbable nature, they are postulated to minimize the risk associated with long-term implantation.
Recent Developments
The market for Bioresorbable Drug Eluting Stents witnessed significant advancements. This progressive trajectory can be attributed to the growing demand for advanced cardiovascular treatments and a continual focus on innovative stent technologies by leading industry players. The adoption of BDES, in particular, emerged as a notable constituent of the broader cardiac care market.
December 2024 : Boston Scientific Corporation announced the release of their next-generation Bioresorbable Drug Eluting Stent, boasting improved deliverability and enhanced patient outcomes
October 2024 : Abbott Laboratories revealed results of their two-year follow-up study, demonstrating the impressive efficacy and safety profile of their Bioresorbable Drug Eluting Stents
August 2024 : Medtronic Plc introduced a new manufacturing technique, setting a new benchmark in the fabrication of Bioresorbable Drug Eluting Stent, promising lower costs and increased production efficiency
Impact of Industry Transitions on the Bioresorbable Drug Eluting Stent Market
As a core segment of the Medical Device industry,
the Bioresorbable Drug Eluting Stent market develops in line with broader industry shifts.
Over recent years, transitions such as Technological Advancements and Strategic Shift towards Minimally Invasive Procedures have redefined priorities
across the Medical Device sector,
influencing how the Bioresorbable Drug Eluting Stent market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Technological Advancements
Cutting edge technologies have brought about a transformation in the Bioresorbable Drug Eluting Stent sector by replacing traditional metallic stents with innovative solutions that address issues such as long term restenosis and stent thrombosis commonly associated with them. The shift to drug eluting stents has not only improved patient outcomes but also revolutionized treatment procedures for the betterment of healthcare practices overall. This advancement has not only impacted the medical field but has also spurred research, in material science as experts seek to develop improved stents using biocompatible materials.
02
Strategic Shift towards Minimally Invasive Procedures
The Bioresorbable Drug Eluting Stent industry has seen a distinct shift towards minimally invasive procedures. Stents placement, once considered a complex surgery, is now achieved with catheterbased procedures with bioresorbable drug eluting stents. This transition has reduced the risk of complications, recovery time, and overall patient discomfort.